Abbott Laboratories 2019 Form 10-K Summary
Business context and reporting period
Abbott filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The company develops, manufactures, and sells healthcare products through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. International sales represented approximately 64% of consolidated net sales. The filing also provides unaudited fourth-quarter results.
Key financial metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Net sales | $31.904 billion | $30.578 billion | +4.3% |
| Operating earnings | $4.532 billion | $3.650 billion | +24.2% |
| Operating margin | 14.2% | 11.9% | +2.3 percentage points |
| Gross margin | 52.5% | 51.3% | +1.2 percentage points |
| Earnings from continuing operations | $3.687 billion | $2.334 billion | +58.0% |
| Diluted EPS from continuing operations | $2.06 | $1.31 | +57.3% |
| Net cash from operating activities | $6.136 billion | $6.300 billion | -2.6% |
| Capital expenditures | $1.638 billion | $1.394 billion | +17.5% |
| Cash and cash equivalents | $3.860 billion | $3.844 billion | Approximately flat |
| Total debt | Approximately $18.1 billion | Approximately $19.6 billion | Reduced by approximately $1.6 billion |
Fourth-quarter 2019 net sales were $8.314 billion, compared with $7.765 billion in the fourth quarter of 2018. Fourth-quarter earnings from continuing operations were $1.049 billion, or $0.59 diluted EPS, compared with $655 million, or $0.37 diluted EPS, in the prior-year quarter.
- Medical Devices sales were $12.239 billion, up 7.6% as reported and 10.5% excluding foreign exchange; operating earnings were $3.769 billion.
- Diagnostic Products sales were $7.713 billion, up 2.9% as reported and 5.9% excluding foreign exchange; operating earnings were $1.912 billion.
- Nutritional Products sales were $7.409 billion, up 2.5% as reported and 4.8% excluding foreign exchange; operating earnings were $1.705 billion.
- Established Pharmaceutical Products sales were $4.486 billion, up 1.4% as reported and 7.3% excluding foreign exchange; operating earnings were $904 million.
- FreeStyle Libre sales were $1.842 billion, an increase of 69.8% excluding foreign exchange.
Material changes versus the prior comparable period
- Revenue growth was driven primarily by volume growth across all segments, partially offset by a 3.2% unfavorable foreign-exchange impact. Price contributed 0.2% to consolidated sales growth.
- Operating margin improved mainly because of lower intangible-amortization expense and lower acquisition-related integration and restructuring costs.
- Intangible-amortization expense declined to $1.936 billion from $2.178 billion. Restructuring and cost-reduction charges increased to approximately $215 million from $153 million.
- Operating cash flow declined because of increased working-capital investment, higher income-tax payments, and pension-contribution timing.
- Abbott repaid approximately $1.6 billion of debt, net of borrowings. It redeemed $2.850 billion of 2.9% notes due 2021 and issued approximately $1.3 billion of euro-denominated debt plus approximately $550 million of yen-denominated term debt.
- Dividends declared increased to $1.32 per share from $1.16 per share, and dividends paid increased to $2.270 billion from $1.974 billion. Abbott repurchased approximately 6.3 million shares for $525 million.
- Beginning in the fourth quarter, Diabetes Care was included in Medical Devices; historical segment results were adjusted accordingly.
- The 2019 effective tax rate was 9.6%, compared with 18.8% in 2018. The 2019 tax provision included an $86 million reduction to the Tax Cuts and Jobs Act transition-tax liability and $68 million of tax expense related to Indian tax legislation.
Guidance, outlook, commentary, risks, and unusual items
Management did not provide a clear consolidated revenue or EPS forecast in the filing. Abbott stated that 2020 priorities include expanding Alinity diagnostics, growing Diabetes Care, Structural Heart, Electrophysiology, and Heart Failure, broadening nutrition products, and expanding branded generic pharmaceuticals in emerging markets. Research and development spending was expected to approximate 7.0% of 2020 sales. Management expects operating cash flow to continue exceeding capital expenditures and cash dividends and expects approximately $387 million of pension contributions in 2020.
- Remaining transition-tax obligations were approximately $1.33 billion, payable over the next seven years. Total contractual obligations were $35.923 billion, including $18.049 billion of debt principal and $9.432 billion of debt interest.
- Abbott had $5 billion of unused unsecured revolving-credit capacity expiring in 2023. Long-term debt ratings were A- from Standard & Poor's and A3 from Moody's.
- Legal and environmental proceedings had an estimated possible-loss range of $95 million to $130 million, with approximately $110 million accrued. Management stated that these matters were not expected to materially affect results.
- Key risks include healthcare pricing and reimbursement pressure, extensive regulatory requirements, product liability and recalls, intellectual-property challenges, manufacturing and supply-chain disruption, foreign-exchange exposure, cybersecurity and data-privacy incidents, acquisition integration, and Abbott's significant indebtedness.
- Goodwill was $23.195 billion and net intangible assets were $17.025 billion at year-end. No significant goodwill impairment was recorded in 2019.
- Critical audit matters included valuation of acquired in-process research-and-development assets and unrecognized tax benefits.
- Abbott's CEO transition was scheduled for March 31, 2020, when Robert B. Ford would become President and CEO and Miles D. White would become Executive Chairman.
Important facts for investors to verify
- Verify the sustainability of growth in FreeStyle Libre, Alinity, Structural Heart, Electrophysiology, and Heart Failure.
- Assess the effect of foreign exchange, pricing pressure, rebates, and healthcare cost-containment measures on reported and organic growth.
- Review debt maturities, refinancing needs, interest costs, and the remaining $1.33 billion transition-tax obligation.
- Evaluate the quality of earnings, including lower amortization, tax benefits, restructuring charges, and other acquisition-related items.
- Monitor goodwill, intangible assets, and in-process research-and-development valuation assumptions for potential impairment.
- Review regulatory, product-liability, legal, environmental, cybersecurity, and manufacturing exposures, including the FDA warning letter concerning the Sylmar facility.
- Confirm that the filing's full consolidated statements and notes support the reported quarterly and annual figures; the source text is a full-year 10-K rather than a standalone quarterly filing.